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Background: Rimonabant reduced body weight and had a favorable impact on progression of total atheroma volume (TAV), but not percent 
atheroma volume (PAV) in the coronary arteries. This analysis investigated changes in measures arterial remodeling in abdominally obese patients in 
the STRADIVARIUS study.
Methods: Changes in vessel wall dimensions and their relationships were characterized and stratified according to inflammatory and adiposity 
related biomarkers.
Results: External elastic membrane (EEM) reduced in both placebo (-7.4±2.3mm3, p=0.001) and rimonabant groups (-8.6±2.3mm3, p<0.001) 
[p=0.70 between groups]. Similarly, lumen volumes reduced in both placebo (-8.2±1.9mm3, p<0.001) and rimonabant groups (-6.4±1.9mm3, 
p<0.001) [p=0.51 between groups]. Changes in TAV were more strongly correlated with changes in EEM (r=0.59, p<0.001) than lumen (r=0.20, 
p<0.001) volumes. A stronger relationship was observed between changes in TAV and lumen volume in patients with higher levels of adiponectin 
(r=0.26 vs. r=0.12, p=0.05) and between changes in TAV and EEM volume in patients with higher levels of CRP (r=0.64 vs. r=0.53, p=0.03). 
Body surface area correlated with changes in EEM (r=0.09, p=0.02) and lumen (r=0.10, p=0.009) volumes, but no relationships were observed 
between changes in vessel dimensions and weight loss. In patients with the highest quartile of PAV, rimonabant significantly reduced TAV (-10±20 
vs. -0.9±22mm3, p=0.006). This was accompanied by significant reduction of EEM (-12±41mm3, p<0.001) and it was not observed in placebo 
(-2.4±39mm3, p=0.26).
Conclusions: Abdominal obese patients demonstrated constrictive remodeling in natural history. Remodeling may be influenced by inflammatory 
factors and adipocytokines. And the finding of plaque regression with rimonabant in the highest PAV group may suggest that remodeling may 
influence the response of plaque to use of anti-atherosclerotic agents.
